Mereo BioPharma Group plc - Sponsored ADR MREO
0.37
0.03
8.82%
as of 25 Sep
- Market cap
- $54.9M
- P/E
- 0.0×
Follow MREO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(69.79%) | (82.21%) | (75.87%) | (67.85%) | |
| (58.41%) | (68.48%) | (65.56%) | (57.73%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(89.28%) | (102.50%) | (105.19%) | (101.16%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.21) | (0.20) | (0.17) | (0.16) | |
Free Cash Flow |
(33.03) | (31.29) | (27.25) | (25.65) | |
Capital Expenditures |
(0.32) | (0.32) | (0.30) | (0.30) | |
Piotroski F-Score |
— | 1.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(34.18%) | (37.81%) | (38.35%) | (43.13%) | |
Accounts Payable Turnover |
0.00 | (0.20) | 0.00 | 0.00 | |
Inventory Turnover |
— | 0.00 | — | — | |
Average Days of Payables |
0.00 | (1,294.00) | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.74 | 0.75 | 0.90 | |
Depreciation/Fixed assets |
1.78 | 4.54 | 7.13 | 12.07 | |
Capex/Depreciation |
(1.03) | (0.51) | (0.46) | (0.46) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.20) | (0.19) | (0.17) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates